Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response

Antimicrobial Agents and Chemotherapy
Inés Herrero-FernándezManuel Leal

Abstract

The response to the HBV vaccine in HIV-infected patients is deficient. Our aim was to analyze whether a suppressive combined antiretroviral treatment (cART) containing maraviroc (MVC-cART) was associated with a better response to HBV vaccine. Fifty-seven patients on suppressor cART were administered the HBV vaccine. The final response, the early response, and the maintenance of the response were assessed. An anti-HBs titer of >10 mIU/ml was considered a positive response. A subgroup of subjects was simultaneously vaccinated against hepatitis A virus (HAV). Lineal regression analyses were performed to determine demographic, clinical, and immunological factors associated with the anti-HBs titer. Vaccine response was achieved in 90% of the subjects. After 1 year, 81% maintained protective titers. Only simultaneous HAV vaccination was independently associated with the magnitude of the response in anti-HBs titers, with a P value of 0.045 and a regression coefficient (B) [95% confident interval (CI)] of 236 [5 to 468]. In subjects ≤50 years old (n = 42), MVC-cART was independently associated with the magnitude of the response (P = 0.009; B [95% CI], 297 [79 to 516]) together with previous vaccination and simultaneous HAV vaccination....Continue Reading

References

Dec 21, 2002·Lancet·Chloe L ThioUNKNOWN Multicenter AIDS Cohort Study
Sep 6, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Edgar Turner OvertonJudith A Aberg
Jan 8, 2008·The Journal of Infectious Diseases·Theodora E M S de Vries-SluijsMarchina E van der Ende
Apr 27, 2010·The Lancet Infectious Diseases·Sabra L KleinAndrew Pekosz
Jun 22, 2010·The Journal of Infectious Diseases·María del Mar del Pozo BaladoYolanda M Pacheco
Nov 26, 2010·Annual Review of Medicine·Steven G Deeks
Jul 13, 2012·The New England Journal of Medicine·Ran ReshefDavid L Porter
Aug 10, 2012·Molecular Medicine·Samantha J WestropNesrina Imami
Sep 6, 2012·Antimicrobial Agents and Chemotherapy·M Concepción Romero-SánchezManuel Leal
Nov 24, 2012·The Lancet Infectious Diseases·Jennifer A WhitakerMark J Mulligan
Jan 15, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Solen KernéisPierre-Yves Boëlle
Mar 4, 2014·The Journal of Infection·Kate RowleyMatthias L Schmid
Mar 22, 2014·The Journal of Infectious Diseases·María Mar Pozo-BaladoManuel Leal
Feb 19, 2015·Human Vaccines & Immunotherapeutics·Peng HeZhongyu Hu
Apr 2, 2015·The Journal of Infectious Diseases·Kevin NajarroNan-ping Weng
Jun 11, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Babafemi O TaiwoUNKNOWN AIDS Clinical Trials Group A5303 Study Team
Jan 26, 2016·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M M Pozo-BaladoY M Pacheco
May 10, 2017·Liver International : Official Journal of the International Association for the Study of the Liver·Guan-Jhou ChenShan-Chwen Chang

❮ Previous
Next ❯

Citations

Jan 7, 2020·Expert Opinion on Drug Metabolism & Toxicology·Miao MiaoGuangdi Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.